Azeria Therapeutics announces appointment of Dr Julian Blagg as VP Drug Discovery

Azeria Therapeutics Limited, a newly formed drug discovery company, today announced the appointment of Dr Julian Blagg as VP Drug Discovery.

Dr Blagg has over 30 years’ experience in medicinal chemistry and drug discovery; he was most recently Deputy Director and Head of Chemistry at The CRUK Cancer Therapeutics Unit at the Institute of Cancer Research (ICR), London, UK where he focused on the discovery of small molecule therapeutics for the treatment of cancer and became a strong advocate for the use of quality chemical probes in biomedical research. Dr Blagg joined the ICR in 2007 following 19 years in the pharmaceutical industry at Pfizer in the US and the UK, where he was responsible for the progression of multiple development candidates into clinical trials across four therapeutic areas.

Stephen Myatt, Chief Executive Officer of Azeria Therapeutics said:

“We are very pleased to welcome Julian to the Azeria management team at this exciting time for the Company. Azeria was created to accelerate R&D and build on the discoveries made by its founder Dr Jason Carroll at CRUK’s Cambridge Institute at the University of Cambridge in the pioneer factor field, an untapped target class in oncology. Having previously been appointed to Azeria’s Scientific Advisory Board, we believe Julian’s commitment to Azeria’s approach combined with his drug discovery experience and track record of delivering small molecule drugs into clinical trials, will add significant value and help us advance our programmes to help cancer patients.”

Dr Julian Blagg, newly appointed VP Drug Discovery of Azeria commented:

“I am delighted to take on the role of VP Drug Discovery at Azeria. I strongly believe in Azeria’s unique and differentiated approach to treating unmet clinical need in breast and prostate cancer and look forward to advancing this innovative research rapidly towards clinical trials and patient benefit.”

Azeria recently raised £4 million ($5.3 million) in a Series A fundraising from the CRT Pioneer Fund, which is managed by Sixth Element Capital LLP. The company aims to use the proceeds to develop a pipeline of small molecules designed to selectively inhibit pioneer factors, with the first target being FOXA1.